Axonics, Inc. (AXNX)

Market Cap	3.02B
Revenue (ttm)	240.92M
Net Income (ttm)	-75.53M
Shares Out	49.53M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,415
Open	61.50
Previous Close	61.07
Day's Range	60.21 - 63.07
52-Week Range	38.41 - 79.92
Beta	0.43
Analysts	Buy
Price Target	85.23 (+39.7%)
Earnings Date	Feb 23, 2023

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Raymond Cohen
• Employees: 517
• Stock Exchange: NASDAQ
• Ticker Symbol: AXNX

Financial Performance

In 2021, Axonics's revenue was $180.29 million, an increase of 61.64% compared to the previous year's $111.54 million. Losses were -$80.07 million, 45.8% more than in 2020.

Analyst Forecast

According to 16 analysts, the average rating for AXNX stock is "Buy." The 12-month stock price forecast is $85.23, which is an increase of 39.70% from the latest price.

Price Target

$85.23

(39.70% upside)

Analyst Consensus: Buy